Experts Debate and Discuss Therapeutic Strategies Using CDK4/6 Inhibitors Across Breast Cancer

Gain up-to-date insights and knowledge from experts on the therapeutic use of CDK4/6 inhibitors in breast cancer treatment through slides, podcasts, and webcasts.

Share

Program Content

Activities

Adjuvant HR+/HER2- EBC Therapy
Individualizing the Current Adjuvant Therapy Algorithm for Patients With HR+/HER2- EBC
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 06, 2024

Expires: December 05, 2025

HR+/HER2- MBC Therapy
Individualizing Therapy for Patients With HR+/HER2- MBC
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 06, 2024

Expires: December 05, 2025

CDK4/6 Inhibitor Related AEs
Managing AEs With CDK4/6 Inhibitors to Promote Adherence and Persistence to Oral Therapy in Your Practice
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 06, 2024

Expires: December 05, 2025

PT Faculty

cover img faculity

Ben Taylor, PA-C, PhD, DFAAPA

Clinical Faculty
Augusta University
Augusta, Georgia
Adjunct Faculty
Rocky Mountain University
Provo, Utah

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.

Lilly

Novartis Pharmaceuticals Corporation